Skip to main content
SpringerLink
Log in

Neuropsychiatric Manifestations in Atypical Parkinsonian Syndromes

  • Chapter
  • First Online:
Neuropsychiatric Symptoms of Movement Disorders

Part of the book series: Neuropsychiatric Symptoms of Neurological Disease ((NSND))

  • 1314 Accesses

Abstract

Neuropsychiatric symptoms occur commonly in atypical parkinsonian disorders. While fluctuating cognition and visual hallucinations are characteristic for Lewy body dementia, insidious frontal lobe signs and subcortical dementia represent the core of neuropsychiatric manifestations in progressive supranuclear palsy. Apraxia is distinctive for corticobasal degeneration, while multiple system atrophy has been considered as disorder devoid of behavioral disturbances until recently. Growing body of evidence reveal the wide range of different cognitive, behavioral, and personality disturbances evolving in each atypical parkinsonism, allowing certain distinctions among disorders despite many overlapping symptoms. Better recognition of neuropsychiatric symptoms is important in terms of developing more effective treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670–6.

    PubMed  CAS  PubMed Central  Google Scholar 

  2. Brown RG, Lacomblez L, Landwehrmeyer BG, Bak T, Uttner I, Dubois B, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain. 2010;133:2382–93.

    PubMed  Google Scholar 

  3. O’Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008;131:1362–72.

    PubMed  Google Scholar 

  4. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol. 2005;4:605–10.

    PubMed  Google Scholar 

  5. Wenning GK, Tison F, Ben Shlomo Y, Daniel E, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997;12:133–47.

    PubMed  CAS  Google Scholar 

  6. Chang CC, Chang YY, Chang WN, Lee YC, Wang YL, Lui CC, et al. Cognitive deficits in multiple system atrophy correlate with frontal atrophy and disease duration. Eur J Neurol. 2009;16:1144–50.

    PubMed  CAS  Google Scholar 

  7. Siri C, Duerr S, Canesi M, Delazer M, Esselink R, Bloem BR, et al. A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. J Neural Transm. 2013;120:613–8.

    PubMed  CAS  Google Scholar 

  8. Kawai Y, Suenaga M, Takeda A, Ito M, Watanabe H, Tanaka F, et al. Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P. Neurology. 2008;70:1390–6.

    PubMed  CAS  Google Scholar 

  9. Petrovic IN, Ling H, Asi Y, Ahmed Z, Kukkle PL, Hazrati LN, et al. Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord. 2012;27:1186–90.

    PubMed  Google Scholar 

  10. Lyoo CH, Jeong Y, Ryu YH, Lee SY, Song TJ, Lee JH, et al. Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy. Brain. 2008;131:438–46.

    PubMed  CAS  Google Scholar 

  11. Pillon B, Gouider-Khouja N, Deweer B, Vidailhet M, Malapani C, Dubois B, et al. Neuropsychological pattern of striatonigral degeneration: comparison with Parkinson’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1995;58:174–9.

    PubMed  CAS  PubMed Central  Google Scholar 

  12. Bak TH, Caine D, Hearn VC, Hodges JR. Visuospatial functions in atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2006;77:454–6.

    PubMed  CAS  PubMed Central  Google Scholar 

  13. Kao AW, Racine CA, Quitania LA, Kramer JH, Christine CW, Miller BL. Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy. Alzheimer Dis Assoc Disord. 2009;23:365–70.

    PubMed  PubMed Central  Google Scholar 

  14. Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain. 2006;129:1040–9.

    PubMed  Google Scholar 

  15. Brenneis C, Egger K, Scherfler C, Seppi K, Schocke M, Poewe W, et al. Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. J Neurol. 2007;254:191–6.

    PubMed  Google Scholar 

  16. Brenneis C, Boesch SM, Egger KE, Seppi K, Scherfler C, Schocke M, et al. Cortical atrophy in the cerebellar variant of multiple system atrophy: a voxel-based morphometry study. Mov Disord. 2006;21:159–65.

    PubMed  Google Scholar 

  17. Schmeichel AM, Buchhalter LC, Low PA, Parisi JE, Boeve BW, Sandroni P, et al. Mesopontine cholinergic neuron involvement in Lewy body dementia and multiple system atrophy. Neurology. 2008;70:368–73.

    PubMed  CAS  Google Scholar 

  18. Mazere J, Meissner WG, Sibon I, Lamare F, Tison F, Allard M, et al. [(123)I]-IBVM SPECT imaging of cholinergic systems in multiple system atrophy: a specific alteration of the ponto-thalamic cholinergic pathways (Ch5-Ch6). Neuroimage Clin. 2013;8:212–7.

    Google Scholar 

  19. Gill CE, Khurana RK, Hibler RJ. Occurrence of depressive symptoms in Shy-Drager Syndrome. Clin Auton Res. 1999;9:1–4.

    PubMed  CAS  Google Scholar 

  20. Benrud-Larson LM, Sandroni P, Schrag A, Low PA. Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov Disord. 2005;20:951–7.

    PubMed  Google Scholar 

  21. Schrag A, Sheikh S, Quinn NP, Lees AJ, Selai C, Mathias C, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2010;25:1077–81.

    PubMed  Google Scholar 

  22. Ghorayeb I, Yekhlef F, Chrysostome V, Balestre E, Bioulac B, Tison F. Sleep disorders and their determinants in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2002;72:798–800.

    PubMed  CAS  PubMed Central  Google Scholar 

  23. Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning GK. Premotor signs and symptoms of multiple system atrophy. Lancet Neurol. 2012;11:361–8.

    PubMed  Google Scholar 

  24. Cochen De Cock V, Debs R, Oudiette D, Leu S, Radji F, Tiberge M, et al. The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophy. Brain. 2011;134:856–62.

    Google Scholar 

  25. Moreno-Lopez C, Santamaria J, Salamero M, Del Sorbo F, Albanese A, Pellecchia MT, et al. Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). Arch Neurol. 2011;68:223–30.

    PubMed  Google Scholar 

  26. Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Spencer B, et al. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy. Exp Neurol. 2012;234:405–16.

    PubMed  CAS  PubMed Central  Google Scholar 

  27. Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ, Smith GE, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer’s disease. Brain. 2007;13:708–19.

    Google Scholar 

  28. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863–72.

    PubMed  CAS  Google Scholar 

  29. Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson’s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2003;74:1215–20.

    PubMed  CAS  PubMed Central  Google Scholar 

  30. Hamilton JM, Salmon DP, Galasko D, Raman R, Emond J, Hansen LA, et al. Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies. Neuropsychology. 2008;22:729–37.

    PubMed  PubMed Central  Google Scholar 

  31. Ballard C, Holmes C, McKeith I, Neill D, O’Brien J, Cairns N, et al. Psychiatric morbidity in dementia with Lewy Bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry. 1999;156:1039–45.

    PubMed  CAS  Google Scholar 

  32. Galvin JE, Malcom H, Johnson D, Morris JC. Personality traits distinguishing dementia with Lewy bodies from Alzheimer disease. Neurology. 2007;68:1895–01.

    PubMed  Google Scholar 

  33. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates Lewy body from Alzheimer’s disease in early-stage dementia? Brain. 2006;129:729–35.

    PubMed  Google Scholar 

  34. Teaktong T, Piggott MA, McKeith IG, Perry RH, Ballard CG, Perry EK. Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. Behav Brain Res. 2005;161:299–05.

    PubMed  CAS  Google Scholar 

  35. Johnson DK, Watts AS, Chapin BA, Anderson R, Burns JM. Neuropsychiatric profiles in dementia. Alzheimer Dis Assoc Disord. 2011;25:326–32.

    PubMed  PubMed Central  Google Scholar 

  36. Caputo M, Monastero R, Mariani E, Santucci A, Mangialasche F, Camarda R, et al. Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types. Acta Psychiatr Scand. 2008;117:455–64.

    PubMed  CAS  Google Scholar 

  37. Nagahama Y, Okina T, Suzuki N, Matsuda M. Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain. 2010;133:557–67.

    PubMed  Google Scholar 

  38. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002;125:391–03.

    PubMed  CAS  Google Scholar 

  39. Burton EJ, McKeith IG, David J, Burn DJ, Williams ED, O’Brien JT. Cerebral atrophy in Parkinson’s disease with and without dementia: a comparison with Alzheimer’s disease, dementia with Lewy bodies and controls. Brain. 2004;127:791–800.

    PubMed  Google Scholar 

  40. Kobayashi K, Sumiya H, Nakano H, Akiyama N, Urata K, Koshino Y. Detection of Lewy body disease in patients with late-onset depression, anxiety and psychotic disorder with myocardial meta-iodobenzylguanidine scintigraphy. Int J Geriatr Psychiatry. 2010;25:55–65.

    PubMed  Google Scholar 

  41. Perry EK, Marshall E, Kerwin J, Smith CJ, Jabeen S, Cheng AV, et al. Evidence of a monoaminergic–cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem. 1990;55:1454–6.

    PubMed  CAS  Google Scholar 

  42. Hynninen MJ, Breitve MH, Rongve A, Aarsland D, Nordhus IH. The frequency and correlates of anxiety in patients with first-time diagnosed mild dementia. Int Psychoger. 2012;24:1771–8.

    Google Scholar 

  43. Fritze F, Ehrt U, Hortobagyi T, Ballard C, Aarsland D. Depressive symptoms in Alzheimer’s disease and Lewy body dementia: a one-year follow-up study. Dement Geriatr Cogn Disord. 2011;32:143–9.

    PubMed  Google Scholar 

  44. Onofrj M, Thomas A, Tiraboschi P, Wenning G, Gambi F, Sepede G, et al. Updates on Somatoform disorders (SFMD) in Parkinson’s disease and dementia with Lewy bodies and discussion of phenomenology. J Neurol Sci. 2011;310:166–71.

    PubMed  Google Scholar 

  45. Boström F, Jönsson L, Minthon L, Londos E. Patients with dementia with Lewy bodies have more impaired quality of life than patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21:150–4.

    PubMed  Google Scholar 

  46. Ikeda M, Mori E, Kosaka K, Iseki E, Hashimoto M, Matsukawa N, et al. Donepezil-DLB Study Investigators. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord. 2013;36:229–41.

    PubMed  CAS  Google Scholar 

  47. Ferman TJ, Smith GE, Kantarci K, Boeve BF, Pankratz VS, Dickson DW. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology. 2013;81:2032–8.

    PubMed  Google Scholar 

  48. Bradshaw JM, Saling M, Anderson V, Hopwood M, Brodtmann A. Higher cortical deficits influence attentional processing in dementia with Lewy bodies, relative to patients with dementia of the Alzheimer’s type and controls. J Neurol Neurosurg Psychiatry. 2006;77:1129–35.

    PubMed  CAS  PubMed Central  Google Scholar 

  49. Park KW, Kim HS, Cheon SM, Cha JK, Kim SH, Kima JW. Dementia with Lewy bodies versus Alzheimer’s disease and Parkinson’s disease dementia: a comparison of cognitive profiles. J Clin Neurol. 2011;7:19–24.

    PubMed  PubMed Central  Google Scholar 

  50. Johns EK, Phillips NA, Belleville S, Goupil D, Babins L, Kelner N, et al. Executive functions in frontotemporal dementia and Lewy body dementia. Neuropsychology. 2009;23:765–77.

    PubMed  Google Scholar 

  51. Lambon Ralph MA, Powell J, Howard D, Whitworth AB, Garrard P, Hodges JR. Semantic memory is impaired in both dementia with Lewy bodies and dementia of Alzheimer’s type: a comparative neuropsychological study and literature review. J Neurol Neurosurg Psychiatry. 2001;70:149–56.

    PubMed  CAS  Google Scholar 

  52. Isella V, Rucci F, Traficante D, Mapelli C, Ferri F, Appollonio IM. The applause sign in cortical and cortical-subcortical dementia. J Neurol. 2013;260:1099–103.

    PubMed  Google Scholar 

  53. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord. 1993;7:69–79.

    PubMed  CAS  Google Scholar 

  54. Pimlott SL, Piggott M, Ballard C, McKeith I, Perry R, Kometa S, et al. Thalamic nicotinic receptors implicated in disturbed consciousness in dementia with Lewy bodies. Neurobiol Dis. 2006;21:50–6.

    PubMed  CAS  Google Scholar 

  55. Dugger BN, Boeve BF, Murray ME, Parisi JE, Fujishiro H, Dickson DW, et al. Rapid eye movement sleep behavior disorder and subtypes in autopsy-confirmed dementia with Lewy bodies. Mov Disord. 2012;27:72–8.

    PubMed  PubMed Central  Google Scholar 

  56. Murray ME, Ferman TJ, Boeve BF, Przybelski SA, Lesnick TG, Liesinger AM, et al. MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. Neurology. 2013;81:1681–9.

    PubMed  Google Scholar 

  57. Pao WC, Boeve BF, Ferman TJ, Lin SC, Smith GE, Knopman DS, et al. Polysomnographic findings in dementia with Lewy bodies. Neurologist. 2013;19:1–6.

    PubMed  PubMed Central  Google Scholar 

  58. Aarsland D, Ballard C, Rongve Broadstock AM, Svenningsson P. Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia. Curr Neurol Neurosci Rep. 2012;12:492–501.

    PubMed  CAS  Google Scholar 

  59. McKeith I, Del Ser T, Spano PF, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031–6.

    PubMed  CAS  Google Scholar 

  60. Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72:41–52.

    PubMed  CAS  Google Scholar 

  61. Aarsland D, Perry R, Larsen JP, McKeith IG, O’Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry. 2005;66:633–7.

    PubMed  Google Scholar 

  62. Emre M, Tsolaki M, Bonuccelli U, Destée A, Tolosa E, Kutzelnigg A; 11018 Study Investigators. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:969–77.

    PubMed  CAS  Google Scholar 

  63. Sharp SI, Ballard CG, Ziabreva I, Piggott MA, Perry RH, Perry EK, et al. Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson’s disease dementia. Dement Geriatr Cogn Disord. 2008;26:330–8.

    PubMed  CAS  Google Scholar 

  64. Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19:591–6.

    PubMed  Google Scholar 

  65. Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013;12:443–53.

    PubMed  Google Scholar 

  66. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain. 2005;128:1247–58.

    PubMed  Google Scholar 

  67. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861–70.

    PubMed  Google Scholar 

  68. Gerstenecker A, Mast B, Duff K, Ferman TJ, Litvan I, ENGENE-PSP Study Group. Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy. Arc Clin Neuropsychol. 2013;28:104–13.

    Google Scholar 

  69. Ghosh BCP, Carpenter RH, Rowe JB. A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy. PLoS One. 2013;8(9):e74486.

    PubMed  CAS  PubMed Central  Google Scholar 

  70. Cordato NJ, Halliday GM, Caine D, Morris JGL. Comparison of motor, cognitive, and behavioral features in progressive supranuclear palsy and Parkinson’s disease. Mov Disord. 2006;21:632–8.

    PubMed  Google Scholar 

  71. Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology. 1996;47:1184–9.

    PubMed  CAS  Google Scholar 

  72. Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2001;13:42–9.

    PubMed  CAS  Google Scholar 

  73. Borroni B, Alberici A, Agosti C, Cosseddu M, Padovani A. Pattern of behavioral disturbances in corticobasal degeneration syndrome and progressive supranuclear palsy. Int Psychogeriatr. 2009;21:463–8.

    PubMed  Google Scholar 

  74. Somme J, Gómez-Esteban JC, Tijero B, Berganzo K, Lezcano E, Zarranz JJ. The applause sign and neuropsychological profile in progressive supranuclear palsy and Parkinson’s disease. Clin Neurol Neurosurg. 2013;115:1230–3.

    PubMed  Google Scholar 

  75. Chiu WZ, Papma JM, de Koning I, Donker KL, Seelaar H, Reijs AE, et al. Midcingulate involvement in progressive supranuclear palsy and tau positive frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2012;83:910–5.

    PubMed  Google Scholar 

  76. Cordato NJ, Duggins AJ, Halliday GM, Morris JG, Pantelis C. Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy. Brain. 2005;128:1259–66.

    PubMed  CAS  Google Scholar 

  77. Srulijes K, Mallien G, Bauer S, Dietzel E, Groger A, Ebersbach G, et al. In vivo comparison of Richardson’s syndrome and progressive supranuclear palsy-parkinsonism. J Neural Transm. 2011;118:1191–7.

    PubMed  CAS  Google Scholar 

  78. Pharr V, Uttl B, Stark M, Litvan I, Fantie B, Grafman J. Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology. 2001;56:957–63.

    PubMed  CAS  Google Scholar 

  79. Josephs KA, Whitwell JL, Eggers SC, Senjem ML, Jack CR Jr. Gray matter correlates of behavioral severity in progressive supranuclear palsy. Mov Disord. 2011;26:493–8.

    PubMed  Google Scholar 

  80. Gerstenecker A, Duff K, Mast B, Litvan I; ENGENE-PSPStudy Group. Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Res. 2013;210:1205–10.

    PubMed  Google Scholar 

  81. Yatabe Y, Hashimoto M, Kaneda K, Honda K, Ogawa Y, Yuuki S, et al. Neuropsychiatric symptoms of progressive supranuclear palsy in a dementia clinic. Psychogeriatrics. 2011;11:54–9.

    PubMed  Google Scholar 

  82. Diederich NJ, Leurgans S, Fan W, Chmura TA, Goetz CG. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry. 2008;23:598–603.

    PubMed  Google Scholar 

  83. Ghosh BCP, Calder AJ, Peers PV, Lawrence AD, Acosta-Cabronero J, Pereira JM, et al. Social cognitive deficits and their neural correlates in progressive supranuclear palsy. Brain. 2012;135:2089–102.

    PubMed  PubMed Central  Google Scholar 

  84. Shany-Ur T, Poorzand P, Grossman SN, Growdon ME, Jang JY, Robin S, Ketelle RS, et al. Comprehension of insincere communication in neurodegenerative disease: lies, sarcasm, and theory of mind. Cortex. 2012;48:132–41.

    Google Scholar 

  85. Cordato NJ, Pantelis C, Halliday GM, Velakoulis D, Wood SJ, Stuart GW, et al. Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain. 2002;125:789–800.

    PubMed  CAS  Google Scholar 

  86. Brenneis C, Seppi K, Schocke M, Benke T, Wenning GK, Poewe W. Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2004;75:246–9.

    PubMed  CAS  PubMed Central  Google Scholar 

  87. Hirano S, Shinotoh H, Shimada H, Aotsuka A, Tanaka N, Ota T, et al. Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia. Brain. 2010;133:2058–68.

    PubMed  Google Scholar 

  88. Litvan I, Phipps M, Pharr V, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57:467–73.

    PubMed  CAS  Google Scholar 

  89. Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert KM, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008;23:942–9.

    PubMed  Google Scholar 

  90. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503.

    PubMed  PubMed Central  Google Scholar 

  91. Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry. 1998;64:184–9.

    PubMed  CAS  PubMed Central  Google Scholar 

  92. Goldmann Gross R, Grossman M. Update on apraxia. Curr Neurol Neurosci Rep. 2008;8:490–6.

    PubMed Central  Google Scholar 

  93. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77.

    PubMed  PubMed Central  Google Scholar 

  94. Murray R, Neumann M, Forman MS, Farmer J, Massimo L, Rice A, et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology. 2007;68:1274–83.

    PubMed  CAS  Google Scholar 

  95. Ling H, O’Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR, Paviour DC, Lees AJ. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010;133:2045–57.

    PubMed  Google Scholar 

  96. Kertesz A, Martinez-Lage P, Davidson W, Munoz DG. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology. 2000;55:1368–75.

    PubMed  CAS  Google Scholar 

  97. Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, Stephen J, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70:327–40.

    PubMed  PubMed Central  Google Scholar 

  98. Pillon B, Blin J, Vidailhet M, Deweer B, Sirigu A, Dubois B, et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer’s disease. Neurology. 1995;45:1477–83.

    PubMed  CAS  Google Scholar 

  99. Litvan I, Cummings JL, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry. 1998;65:717–21.

    PubMed  CAS  PubMed Central  Google Scholar 

  100. Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: differentiation from Alzheimer’s disease. Neurology. 1996;46:720–6.

    PubMed  CAS  Google Scholar 

  101. Armstrong N, Schupf N, Grafman J, Huey ED. Caregiver burden in frontotemporal degeneration and corticobasal syndrome. Dement Geriatr Cogn Disord. 2013;36:310–8.

    PubMed  Google Scholar 

  102. Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, Williams-Gray CH, et al. The Addenbrooke’s cognitive examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders. J Neurol Neurosurg Psychiatry. 2013;84:544–51.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Movement Disorders Department, Neurology Clinic, Clinical Center of Serbia, Dr. Subotica 6, Belgrade, 11000, Serbia

    Iva Stankovic MD

  2. Division of Neurobiology, Department of Neurology, Innsbruck Medical University, Anichstrasse 35, Innsbruck, A-6020, Austria

    Gregor K. Wenning MD, PhD, MSC

Authors
  1. Iva Stankovic MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregor K. Wenning MD, PhD, MSC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregor K. Wenning MD, PhD, MSC .

Editor information

Editors and Affiliations

  1. Department of Neurology, Technische Universität Dresden, Dresden, Sachsen, Germany

    Heinz Reichmann

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Stankovic, I., Wenning, G.K. (2015). Neuropsychiatric Manifestations in Atypical Parkinsonian Syndromes. In: Reichmann, H. (eds) Neuropsychiatric Symptoms of Movement Disorders. Neuropsychiatric Symptoms of Neurological Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-09537-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-09537-0_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-09536-3

  • Online ISBN: 978-3-319-09537-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation